Suppr超能文献

人类醛固酮生物合成的先天性缺陷。

Inborn errors of aldosterone biosynthesis in humans.

作者信息

Shizuta Y, Kawamoto T, Mitsuuchi Y, Miyahara K, Rösler A, Ulick S, Imura H

机构信息

Department of Medical Chemistry, Kochi Medical School, Nankoku, Japan.

出版信息

Steroids. 1995 Jan;60(1):15-21. doi: 10.1016/0039-128x(94)00023-6.

Abstract

Corticosterone methyl oxidase (CMO) type I and type II deficiencies are inborn errors at the penultimate and ultimate steps in the biosynthesis of aldosterone in humans. Recently, steroid 18-hydroxylase (P450C18), or aldosterone synthase (P450aldo), was shown to be a multifunctional enzyme catalyzing these two steps of aldosterone biosynthesis, i.e., the conversion of corticosterone to 18-hydroxycorticosterone and the subsequent conversion of 18-hydroxycorticosterone to aldosterone. This observation suggests that CMO I and CMO II deficiencies are derived from two different mutations in the P450C18 gene (CYP11B2). To elucidate whether or not this is the case, we performed molecular genetic studies on CYP11B2 of both types of patients. Nucleotide sequence analysis has indicated that the gene of CMO I deficient patients is completely inactivated by a frameshift to form a stop codon due to a 5-bp nucleotide deletion in exon 1. Sequence analysis of CYP11B2 of CMO II deficient patients has revealed two point mutations, CGG-->TGG (Arg181-->Trp) in exon 3 and GTG-->GCG (Val386-->Ala) in exon 7. CYP11B1, the gene for steroid 11 beta-hydroxylase (P45011 beta) which was previously postulated to be the target for CMO II deficiency, is not impaired in these two types of patients. Expression studies using the corresponding mutant cDNAs have shown that CMO I deficient patients are null mutants with a complete lack of P450C18 whereas CMO II deficient patients are leaky mutants with an altered P450C18 activity.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

Ⅰ型和Ⅱ型皮质酮甲基氧化酶(CMO)缺乏症是人类醛固酮生物合成倒数第二步和最后一步的先天性缺陷。最近,类固醇18-羟化酶(P450C18),即醛固酮合酶(P450aldo),被证明是一种多功能酶,催化醛固酮生物合成的这两个步骤,即将皮质酮转化为18-羟皮质酮,以及随后将18-羟皮质酮转化为醛固酮。这一观察结果表明,Ⅰ型和Ⅱ型CMO缺乏症源自P450C18基因(CYP11B2)中的两种不同突变。为了阐明是否如此,我们对这两种类型患者的CYP11B2进行了分子遗传学研究。核苷酸序列分析表明,Ⅰ型CMO缺乏症患者的基因由于外显子1中5个碱基对的核苷酸缺失而发生移码,从而完全失活,形成终止密码子。Ⅱ型CMO缺乏症患者的CYP11B2序列分析显示了两个点突变,外显子3中的CGG→TGG(Arg181→Trp)和外显子7中的GTG→GCG(Val386→Ala)。类固醇11β-羟化酶(P45011β)的基因CYP11B1,之前被认为是Ⅱ型CMO缺乏症的靶点,在这两种类型的患者中并未受损。使用相应突变cDNA的表达研究表明,Ⅰ型CMO缺乏症患者是完全缺乏P450C18的无效突变体,而Ⅱ型CMO缺乏症患者是P450C18活性改变的渗漏突变体。(摘要截短于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验